List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 248 studies with search of:   Croatia
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting A Study to Evaluate CG5503 in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
Conditions: Tumor;   Pain
Interventions: Drug: CG5503 ER;   Drug: Placebo to match CG5503;   Drug: Morphine Sulphate CR;   Drug: Placebo to match Morphine Sulphate CR
2 Completed An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Conditions: Major Depressive Disorder;   Psychotic Disorders
Intervention: Drug: Mifepristone
3 Completed A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Conditions: Pain;   Knee Osteoarthritis
Interventions: Drug: CG5503, centrally acting analgesic;   Drug: Placebo;   Drug: CG5503;   Drug: Oxycodone
4 Active, not recruiting Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-Based Subunit Influenza Vaccines in Healthy Children and Adolescents
Condition: Influenza
Interventions: Biological: Cell culture-derived Influenza Virus subunit vaccine;   Biological: egg derived vaccine
5 Recruiting A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
6 Recruiting BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Condition: Multiple Sclerosis
Interventions: Drug: laquinimod;   Drug: placebo;   Drug: Interferon β-1a (Avonex®)
7 Completed SLV308 for Treatment of Patients With Early Parkinson's Disease
Condition: Early Stage Parkinson's Disease
Interventions: Drug: pardoprunox;   Drug: Pardoprunox;   Drug: Pardoprunox;   Drug: Placebo
8 Active, not recruiting An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
Condition: Early Stage Parkinson's Disease
Intervention: Drug: Pardoprunox
9 Active, not recruiting Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Condition: Breast Cancer
Intervention: Drug: lapatinib (GW572016)
10 Recruiting Non-Interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
Condition: Asthma
Intervention: Drug: Symbicort
11 Completed An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Condition: Major Depressive Disorder
Intervention: Drug: Mifepristone
12 Terminated Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
Condition: Ulcerative Colitis
Intervention: Drug: Visilizumab (Nuvion®; HuM291)
13 Completed MICHELANGELO OASIS-6 : FOndaparinux in ST Elevation Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Drug: fondaparinux sodium;   Drug: heparin;   Drug: Glucose-insulin-potassium (GIK)
14 Recruiting Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Condition: Hypertension
Intervention: Drug: Amlodipine besylate/atorvastatin calcium single pill combination
15 Recruiting Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin;   Drug: Placebo
16 Recruiting Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Intervention:
17 Recruiting Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)
18 Recruiting REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Rebif New Formulation (RNF);   Drug: Rebif New Formulation (RNF);   Drug: Placebo
19 Terminated Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
Conditions: Dyslipidemia;   Glucose Metabolism Disorder
Interventions: Drug: fenofibrate (F) + metformin (M) hydrochloride fixed combination;   Drug: Rosiglitazone
20 Active, not recruiting RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Condition: Type II Diabetes
Interventions: Drug: rosiglitazone;   Drug: metformin;   Drug: sulfonylurea

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services